2026 Biopharma Competition 
MedCity News
AUGUST 15, 2024
The first 10 drugs selected for Medicare price negotiations now have new prices set to take effect in 2026. Industry observers note that most of these drugs are older products facing generic competition soon, so greater industry impact will come as the program expands to more drugs in years to come.
European Pharmaceutical Review
AUGUST 22, 2022
However, China and India are set to be fierce competition over the next decade, with 30 percent of respondents suggesting they would offshore >50 percent of clinical trials and operations to India, China or other lower-cost countries over the next five years.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JULY 21, 2023
The company intends to invest approximately $90 million at its site in Ljubljana, Slovenia, to establish a dedicated Sandoz Biopharma Development Center by 2026. They drive competition and cost savings, helping to address the rising financial pressures faced by global healthcare systems.
Clarivate
OCTOBER 25, 2023
The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. exclusions exist for orphan drug designation and biosimilar competition ).
Clarivate
APRIL 24, 2023
Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. billion deal to acquire Oak Street Health, a value-based primary-care company focused on treating Medicare patients. In January 2023, VillageMD acquired Summit Health for $8.9
Clarivate
AUGUST 20, 2024
Price negotiations will be staggered over time, beginning with this initial list of ten Part D drugs that takes effect in 2026 (Part D is the prescription drug coverage component of Medicare, a federal health insurance program for people 65 and older which covers nearly 1 in 5 Americans). These ten drugs cost Medicare Part D nearly $46.8
Clarivate
OCTOBER 17, 2024
As California Attorney General from 2011 to 2017, Harris was a forceful opponent of healthcare industry consolidation, both vertical and horizontal, believing that mergers of hospitals, physician groups and insurers would damage competition and raise prices for care. 31, 2024, and providers and payers are pushing for an extension.
Expert insights. Personalized for you.
130 
Let's personalize your content